SeaStar Medical Closes $4 Million Registered Direct Offering and Private Placement; Lucosky Brookman Serves as Company Counsel
SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure, successfully closed its $4 million financing through a registered direct offering and concurrent private placement.
The offering included the issuance and sale of 5,242,464 shares of common stock (or common stock equivalents) at a purchase price of $0.763 per share, priced at-the-market under Nasdaq rules. In a concurrent private placement, SeaStar Medical issued unregistered warrants to purchase up to 5,242,464 shares of common stock at an exercise price of $0.638 per share. The warrants are immediately exercisable and will expire five years following the effective date of the resale registration statement covering the underlying shares.
Lucosky Brookman LLP served as legal counsel to SeaStar Medical. H.C. Wainwright & Co. acted as the exclusive placement agent.
The Company intends to use the net proceeds for general corporate purposes, including working capital and capital expenditures.